Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, Wulf O. Böcher, Geert D’Haens et al.|The Lancet|2017

Cited by 449